LU84447A1 - Stabilisierte insulinpraeparate und verfahren zur herstellung derselben - Google Patents

Stabilisierte insulinpraeparate und verfahren zur herstellung derselben Download PDF

Info

Publication number
LU84447A1
LU84447A1 LU84447A LU84447A LU84447A1 LU 84447 A1 LU84447 A1 LU 84447A1 LU 84447 A LU84447 A LU 84447A LU 84447 A LU84447 A LU 84447A LU 84447 A1 LU84447 A1 LU 84447A1
Authority
LU
Luxembourg
Prior art keywords
insulin
solution according
insulin solution
solution
formula
Prior art date
Application number
LU84447A
Other languages
German (de)
English (en)
French (fr)
Inventor
Philip Edgar Hansen
Svend Havelund
Jens Jorgen Vejlgaard
Original Assignee
Novo Ind Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Ind Sa filed Critical Novo Ind Sa
Publication of LU84447A1 publication Critical patent/LU84447A1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
LU84447A 1981-10-30 1982-10-29 Stabilisierte insulinpraeparate und verfahren zur herstellung derselben LU84447A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK478681 1981-10-30
DK478681 1981-10-30
DK324782 1982-07-20
DK324782 1982-07-20

Publications (1)

Publication Number Publication Date
LU84447A1 true LU84447A1 (fr) 1983-06-13

Family

ID=26066963

Family Applications (1)

Application Number Title Priority Date Filing Date
LU84447A LU84447A1 (fr) 1981-10-30 1982-10-29 Stabilisierte insulinpraeparate und verfahren zur herstellung derselben

Country Status (20)

Country Link
US (1) US4614730A (fi)
AT (1) AT382079B (fi)
AU (1) AU549593B2 (fi)
BE (1) BE894885A (fi)
CA (1) CA1198673A (fi)
CH (1) CH649922A5 (fi)
DE (1) DE3240177A1 (fi)
ES (1) ES516963A0 (fi)
FI (1) FI80595C (fi)
FR (1) FR2515517B1 (fi)
GB (1) GB2107985B (fi)
GR (1) GR77360B (fi)
IE (1) IE54029B1 (fi)
IT (1) IT1153315B (fi)
LU (1) LU84447A1 (fi)
NL (1) NL193099C (fi)
NO (1) NO168086C (fi)
NZ (1) NZ202328A (fi)
PT (1) PT75766B (fi)
SE (1) SE460576B (fi)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4914084A (en) * 1984-05-09 1990-04-03 Synthetic Blood Corporation Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body
EP0179904A1 (en) * 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
FR2605449B1 (fr) * 1986-10-17 1988-12-02 Thomson Cgr Bloc magnetique a aimantation ajustable pour la production d'un champ magnetique permanent dans une zone d'interet
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
WO1991016453A1 (en) * 1990-04-17 1991-10-31 Analytical Control Systems, Inc. Coagulation assays and reagents
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
DK0748213T3 (da) 1994-03-07 2004-08-02 Nektar Therapeutics Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
KR101801426B1 (ko) 2010-07-14 2017-12-20 인스티투트 오브 마타리아 메디카, 차이니즈 아카데미 오브 메디칼 사이언스 인슐린-지질 복합물 및 그의 제조방법과 그의 제제
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin
CA3070156A1 (en) 2017-07-20 2019-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusam Ltd. Pharmaceutical film compositions for delivery of lipophilic compounds into and/or across the skin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2563070A (en) * 1947-12-19 1951-08-07 Chicago Medical School Antidiabetic
GB1285023A (en) * 1968-08-09 1972-08-09 Novo Terapeutisk Labor As Improvements in or relating to injectable insulin preparations
US3758683A (en) * 1971-04-30 1973-09-11 R Jackson Insulin product
JPS50116028A (fi) * 1974-02-26 1975-09-11
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4164573A (en) * 1975-06-13 1979-08-14 Galinsky Alvin M Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
CH621479A5 (fi) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (fi) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
DE2952119A1 (de) * 1979-12-22 1981-07-09 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige protein-loesungen
EP0032622B1 (en) * 1979-12-20 1985-08-14 Dennis Chapman Polymerisable phospholipids and polymers thereof, methods for their preparation, methods for their use in coating substrates and forming liposomes and the resulting coated substrates and liposome compositions

Also Published As

Publication number Publication date
FI80595C (fi) 1990-07-10
NL8203944A (nl) 1983-05-16
FI823702A0 (fi) 1982-10-29
FR2515517B1 (fr) 1987-07-03
NO168086C (no) 1992-01-15
US4614730A (en) 1986-09-30
ATA392482A (de) 1986-06-15
FI823702L (fi) 1983-05-01
PT75766A (en) 1982-11-01
DE3240177C2 (fi) 1993-07-22
IE822602L (en) 1983-04-30
NL193099C (nl) 1998-11-03
NO823603L (no) 1983-05-02
IT1153315B (it) 1987-01-14
AU8986182A (en) 1983-05-05
AT382079B (de) 1987-01-12
SE8206168L (sv) 1983-05-01
FR2515517A1 (fr) 1983-05-06
IE54029B1 (en) 1989-05-24
DE3240177A1 (de) 1983-05-11
FI80595B (fi) 1990-03-30
AU549593B2 (en) 1986-01-30
CH649922A5 (de) 1985-06-28
NZ202328A (en) 1985-07-12
SE460576B (sv) 1989-10-30
ES8403025A1 (es) 1984-03-01
NL193099B (nl) 1998-07-01
IT8223990A0 (it) 1982-10-29
SE8206168D0 (sv) 1982-10-29
GB2107985A (en) 1983-05-11
CA1198673A (en) 1985-12-31
PT75766B (en) 1985-12-09
ES516963A0 (es) 1984-03-01
GR77360B (fi) 1984-09-11
NO168086B (no) 1991-10-07
GB2107985B (en) 1984-11-14
BE894885A (fr) 1983-04-29

Similar Documents

Publication Publication Date Title
LU84447A1 (fr) Stabilisierte insulinpraeparate und verfahren zur herstellung derselben
DE3303860C2 (fi)
EP0357978B1 (de) Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus
DE69808695T2 (de) Stabile Insulinformulierungen
DE69617723T2 (de) Wachsumsfaktoren enthaltende gelformulierungen
DE602005002495T2 (de) Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat
DE68904922T2 (de) Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
DE69728783T2 (de) Verbesserte arzneimittel
DE69621942T2 (de) Verbessertes herstellungsverfahren und zusammensetzung für therapeutisches cisplatin (cddp)
DE69827357T2 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
DE2415101A1 (de) Pharmazeutische zusammensetzungen
DE60114249T2 (de) Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
DE60116483T2 (de) Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
DE69420872T2 (de) Hgh enthaltende pharmazeutische zubereitungen
DE69129953T2 (de) Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus
EP1206244B1 (de) Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon
DE69528048T2 (de) Peptid oder protein enthaltende hyaluronsäure mit niedrigem molekulargewicht
DE69417397T2 (de) Lösung, die igf-1 enthält
EP0166971B1 (de) Insulinzubereitungen, Verfahren zu deren Herstellung und deren Verwendung
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
DE60101979T2 (de) Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel
DE60001489T2 (de) Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
DE69231263T2 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen
WO2000056325A2 (de) Ibuprofen-lösung
DE2546474A1 (de) Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung